Investment Thesis
Artelo Biosciences exhibits severe financial distress with negative stockholders' equity of -$1.3M, indicating liabilities exceed assets. The company has no revenue generation, sustained operating losses of -$11.4M, and negative free cash flow of -$8.5M, with only $600K in cash reserves providing minimal runway. The combination of insolvency, cash burn, and complete lack of revenue demonstrates fundamental business failure.
ARTL Strengths
- Recent insider activity with 8 Form 4 filings suggests some management engagement
- No long-term debt burden reducing bankruptcy triggers
- Pharmaceutical sector exposure could have potential if R&D yields results
ARTL Risks
- Negative stockholders' equity indicates technical insolvency and balance sheet restructuring risk
- Zero revenue with ongoing operating losses of -$11.4M indicates no commercialized products
- Cash position of $600K with -$8.5M operating cash burn provides less than 1 month of runway
- Extreme negative ROA of -459.8% reflects severe capital inefficiency
- Liquidity crisis with current ratio of 0.17x indicating inability to meet short-term obligations
Key Metrics to Watch
- Cash runway and path to profitability/partnerships
- Revenue recognition or clinical trial milestones
- Balance sheet restructuring or equity raise announcements
ARTL Financial Metrics
ARTL Profitability Ratios
ARTL Balance Sheet & Liquidity
ARTL 5-Year Financial Trend
5-Year Trend Summary: ARTELO BIOSCIENCES, INC.'s revenue has remained relatively flat over the 5-year period, with a 0% decline. The most recent EPS of $-18.30 indicates the company is currently unprofitable.
ARTL Growth Metrics (YoY)
ARTL Capital Allocation
ARTL SEC Filings
Access official SEC EDGAR filings for ARTELO BIOSCIENCES, INC. (CIK: 0001621221)